Cytokine armored dual-CAR γδT cells target CD70 and CSPG4 in advanced epithelial ovarian cancer

Project summary

A breakthrough is on the horizon for advanced ovarian cancer patients. With current treatments falling short, a novel therapy harnessing gamma delta (gd) T cells offers hope. Unlike traditional CAR-T cells, gd CAR-T cells can recognize cancer in multiple ways and with fewer side effects. Our innovative therapy is tailored to tackle ovarian cancer’s challenges, with a built-in safety switch to protect patients. Early studies show promising results, paving the way for further research and a potential game-changing treatment. With a dedicated team driving this initiative, we aim to improve outcomes and deliver a brighter future for ovarian cancer patients.

This grant was made possible in part by generous donations from Benton Clark in loving memory of Johanna M. Clark; Hope for Heather in memory of Heather Weeks; and Team MB Hunt for the Cure in memory of Maribeth Tobolski.